Table 1.
Product | Target | Institution | Development phase |
---|---|---|---|
IMO-2125 CpG-3’-3’ fusion |
TLR9/CTLA-4 | Idera Pharmaceutical | Phase 1/2 (metastatic melanoma): in combination with ipilimumab |
SD-101 CpG-C |
TLR9/PD-1 | Dynavax | Phase 1/2 (metastatic melanoma): in combination with pembrolizumab |
MGN1703 double loop CpG |
TLR9/CTLA-4 | Mologene AG | Phase 1 (advanced solid tumors): in combination with ipilimumab |
CMP-001 CpG-A/VLP |
TLR9/PD-1 | Checkmate Pharmaceuticals | Phase 1/2 (advanced melanoma): in combination with pembrolizumab |
CSI-2 CpG-B conjugate |
TLR9/STAT3 | City of Hope | Phase 1 planned for 2019 (Non-Hodgkin’s B cell lymphoma) |